Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Submits New Formulation For Alzheimer’s Drug Aricept In Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai's new oral jelly formulation of Alzheimer's drug Aricept (donepezil) will have no effect on the Japanese company's position in the market, a pharmaceutical analyst and researcher for KBC Securities Japan told PharmAsia News. "It's just a reformulation from an existing product, that already has a lot of patients," analyst Philip Hall said. Eisai announced its application for the new formulation in Japan March 13. The company will not apply for the new formulation in any other country, Eisai Spokeswoman Chie Suzuki told PharmAsia News. "We consider the particular needs of patients in each country and region." "We developed the new formula for this drug in response to the particular needs of patients in Japan," she said. In Japan, Aricept is already available in tablets, fine granules and orally disintegrating tablets. The new formula is the first Alzheimer's disease treatment available in an oral jelly formulation, according to Eisai.
Advertisement

Related Content

Eisai Fights To Maintain Aricept Patent Rights While Resuming Development On Next Generation Therapy
Eisai Fights To Maintain Aricept Patent Rights While Resuming Development On Next Generation Therapy
China And India Next Targets For Eisai’s Global Plan 
China And India Next Targets For Eisai’s Global Plan 
Advertisement
UsernamePublicRestriction

Register

SC068034

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel